Seelos Therapeutics (SEEL)
(Real Time Quote from BATS)
$0.24 USD
-0.02 (-8.64%)
Updated Sep 4, 2024 11:04 AM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
SEEL 0.24 -0.02(-8.64%)
Will SEEL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SEEL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SEEL
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
SEEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SEEL
Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Biotech Alert: Searches spiking for these stocks today
Earnings week ahead: Zoom, Lowe's, Target, Baidu, XPeng, Zim Integrated and more
SEEL Stock Earnings: Seelos Therapeutics Beats Revenue for Q2 2024